Titan Receives SBIR Grant to Investigate Long Term Treatment for Parkinson's Disease
SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease.

First Combined Pharma Trial Data on Brain Disease Made Widely Available to Researchers Today
Embargoed for 12:01 a.m. EDT Friday, June 11, 2010 WASHINGTON, June 11 /PRNewswire-USNewswire/ -- A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials was released today by the Coalition Against Major Diseases (http://c-path.org/CAMD.cfm).  This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.  It is also the first effort of its kind to create a voluntary industry data standard that will help accelerate new treatment research on brain disease.  The data will enable researchers to more accurately predict the true course of Alzheimer's, Parkinson's, Huntingto...